Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation

We recently found that nucleosomes directly block access of CRISPR/Cas9 to DNA (Horlbeck et al., 2016). Here, we build on this observation with a comprehensive algorithm that incorporates chromatin, position, and sequence features to accurately predict highly effective single guide RNAs (sgRNAs) for...

Full description

Saved in:
Bibliographic Details
Published in:eLife Vol. 5
Main Authors: Horlbeck, Max A, Gilbert, Luke A, Villalta, Jacqueline E, Adamson, Britt, Pak, Ryan A, Chen, Yuwen, Fields, Alexander P, Park, Chong Yon, Corn, Jacob E, Kampmann, Martin, Weissman, Jonathan S
Format: Journal Article
Language:English
Published: England eLife Sciences Publications Ltd 23-09-2016
eLife Sciences Publications, Ltd
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We recently found that nucleosomes directly block access of CRISPR/Cas9 to DNA (Horlbeck et al., 2016). Here, we build on this observation with a comprehensive algorithm that incorporates chromatin, position, and sequence features to accurately predict highly effective single guide RNAs (sgRNAs) for targeting nuclease-dead Cas9-mediated transcriptional repression (CRISPRi) and activation (CRISPRa). We use this algorithm to design next-generation genome-scale CRISPRi and CRISPRa libraries targeting human and mouse genomes. A CRISPRi screen for essential genes in K562 cells demonstrates that the large majority of sgRNAs are highly active. We also find CRISPRi does not exhibit any detectable non-specific toxicity recently observed with CRISPR nuclease approaches. Precision-recall analysis shows that we detect over 90% of essential genes with minimal false positives using a compact 5 sgRNA/gene library. Our results establish CRISPRi and CRISPRa as premier tools for loss- or gain-of-function studies and provide a general strategy for identifying Cas9 target sites.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Calico Life Sciences LLC, South San Francisco, United States.
ISSN:2050-084X
2050-084X
DOI:10.7554/elife.19760